Programa de Pós-Graduação em Ciências Farmacêuticas - PPGCF/ICS
URI Permanente desta comunidadehttps://repositorio.ufpa.br/handle/2011/2312
O Programa de Pós-Graduação em Ciências Farmacêuticas (PPGCF) vinculado ao Instituto de Ciências da Saúde (ICS) da Universidade Federal do Pará (UFPA) apresenta um auto-impacto de inserção regional uma vez que se trata do único PPGCF na Região Norte pelo grande potencial de utilização da biodiversidade na região amazônica. Além de favorecer a fixação e atração de profissionais qualificados na área de Ciências Farmacêuticas na Região Amazônica.
Navegar
Navegando Programa de Pós-Graduação em Ciências Farmacêuticas - PPGCF/ICS por Assunto "Adesão ao tratamento"
Agora exibindo 1 - 2 de 2
- Resultados por página
- Opções de Ordenação
Item Acesso aberto (Open Access) Avaliação da adesão à terapia medicamentosa em hipertensos de unidades de saúde do distrito DAGUA no município de Belém-Pará(Universidade Federal do Pará, 2012-08-30) SOUSA, Patrick Luis Cruz de; SILVA, Marcos Valério Santos da; http://lattes.cnpq.br/0379783635000306; ANDRADE, Marcieni Ataíde de; http://lattes.cnpq.br/8514584872100128Adherence to pharmacotherapy in several chronic diseases, especially hypertension (SH), has great importance for the prevention, reduction and control of diseases and complications, thus reducing cardiovascular morbidity and mortality. Evaluate the modifiable and non-modifiable factors that contribute to a better adherence to medication in patients DAGUA district in Belém-PA, can serve as the basis for qualification of pharmaceutical care, clinical management, public politics, actions and plans in services public health in order to improve patient compliance. We conducted a descriptive transversal observational and quantitative analysis with a random sample of 227 patients enrolled in the program HIPERDIA, from March 2010 to August 2011, where we assessed the knowledge and the degree of adherence to drug therapy using the tests Morisky and Green (TMG) and the Batalla test relating to socioeconomic, lifestyle, and esquipe health service and patient-related factors. The study population was characterized predominantly by women (69.5%) aged above 60 years (44.5%), mixed race (48%), married (44.9%), retired (43.6%) and with low educational level, being (55.1%) with incomplete primary education. Of the total persons (63.46%) had uncontrolled blood pressure. Not adhere to treatment (66.9%) according to test Morisky and Green (72.38%) by the test Batalla.Item Acesso aberto (Open Access) Exposição a rifampicina e adesão ao tratamento da tuberculose pulmonar(Universidade Federal do Pará, 2020-08-28) ELIAS, Gisely France Abrantes; VIEIRA , José Luiz Fernandes; http://lattes.cnpq.br/2739079559531098; https://orcid.org/ 0000-0003-4842-8762; VASCONCELOS, Flávio de; http://lattes.cnpq.br/3695753129639448; https://orcid.org/ 0000-0001-9568-6268Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, generally affecting the lungs and leading to death. The Ministry of Health recommends for the treatment of new cases of pulmonary tuberculosis the association of chemotherapy drugs administered in two phases: the intensive one, which lasts two months, and Rifampicin (600 mg), Isoniazid (300 mg), Pyrazinamide (1600 mg) and Ethambutol (1100 mg) (2RHZE) and maintenance, for four months, when Rifampicin (600 mg) and Isoniazid (300 mg) (4RH) are administered. The full dose of medication is indicated for patients over 50 kg. A determinant of therapeutic success is the exposure of the bacillus for a certain period of time to effective concentrations of chemotherapeutic agents, that is, above the minimum inhibitory concentration (MIC), which in this case of rifampicin ranges from 0.05 µg / ml to 0.5 µg / ml, in addition, studies have shown that maximum plasma drug concentrations above 8.0 µg / ml are associated with a high rate of therapeutic success. However, there is a high intra and interindividual variation in the plasma concentrations of rifampicin in the usual therapeutic doses, caused by factors related to the patient and the drug dispensed, which can interfere with exposure, as well as the administered doses and anthropometric measurements of the patients. The aim of the present study was to investigate the factors that influence plasma concentration when exposed to rifampicin in the treatment of pulmonary tuberculosis in a Basic Health Unit in Belém / Pa. A cross-sectional and observational study was carried out of 70 cases of subjects of both sexes, with clinical, radiological and laboratory diagnosis of tuberculosis by M. tuberculosis, distributed in the intensive and maintenance phases of treatment. Plasma concentrations of rifampicin were determined, as well as anthropometric measurements of weight, height, fat percentage and abdominal circumference of each individual and the application of the Morisky-Green Test to assess adherence. Thus, the sample included in the study was composed mainly of adult men with low education and income. Plasma concentrations of rifampicin were above the minimum inhibitory concentration of M. tuberculosis indicating adequate exposure to the drug, which can be measured by the high proportion of patients who had smear conversion at the end of the first month of treatment. Sex was not a predictor of variation in plasma rifampin concentrations. The treatment phase was considered to be a predictor of variation in plasma drug concentrations. The concentrations of rifampicin were not associated with the Body Mass Index, waist circumference and fat percentage both in patients in the intensive phase and in those in maintenance of treatment. Adherence to tuberculosis treatment was 88.1% and 82.14% in patients in the intensive and maintenance phases, respectively. Plasma concentrations of rifampicin were not associated with the Morisky-Green Test.